{"transactions":[{"id":1044092,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T15:34:21.000Z","date":"2025-04-09","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.7297,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-024081","document":"form4-09102025_070918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588925024081/form4-09102025_070918.xml","form_type":"4"}},{"id":2102640,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":1750,"price":1.25,"value":2187.5,"ownership":{"direct":true},"balance_after":1750,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102639,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.24,"value":3100.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":40209,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102638,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":37709,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102637,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":40209,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2102636,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-11-29T07:00:11.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":2500,"price":1.25,"value":3125.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":37709,"source":{"system":"sec-edgar","filing":"0001415889-22-011810","document":"form4-11292022_071101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000141588922011810/form4-11292022_071101.xml","form_type":"4"}},{"id":2107146,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-22T17:44:53.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."}],"balance_after":162660,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003242","document":"es220307154_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014222003242/es220307154_4-flynnp.xml","form_type":"4"}},{"id":2674226,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to buy)","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":692639,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":692639,"derivative":{"exercise_price":3.08,"expiration_date":"2025-10-22","underlying":"Common Stock","underlying_shares":692639},"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674225,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to buy)","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":692639,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":692639,"derivative":{"exercise_price":3.08,"expiration_date":"2025-10-22","underlying":"Common Stock","underlying_shares":692639},"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674224,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":35209,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Lindsay Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":35209,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674223,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":35209,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Whitney Pritchard Nash Flynn 2010 Trust of which the Reporting Person is trustee."}],"balance_after":35209,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}},{"id":2674222,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":75582,"kind":"person","name":"Flynn Patrick John","position":1,"cik":"0001864871","reported_name":"Flynn Patrick John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:46:10.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":362332,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Nash-Flynn Investments, LLC of which the Reporting Person is the sole member."}],"balance_after":362332,"source":{"system":"sec-edgar","filing":"0000950142-21-001938","document":"es210157182_4-flynnp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864871/000095014221001938/es210157182_4-flynnp.xml","form_type":"4"}}]}